Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on December 21, 2020, regarding events occurring on December 17, 2020. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the appointment of Brian Schwartz, M.D., as a Class 2 Director effective December 17, 2020, serving until the 2023 annual meeting. Dr. Schwartz brings significant experience in oncology drug development, having previously served as Chief Medical Officer at ArQule Inc. and Ziopharm Oncology, Inc.
Compensatory Arrangements and Outlook
- Equity Grant: Dr. Schwartz was granted an option to purchase 5,200 shares of common stock at an exercise price of $4.13 per share. The options vest on the first anniversary of the grant date and expire on December 17, 2030.
- Cash Compensation: An annual fee of $45,000 is established for his services as a non-executive director, plus reimbursement for customary business expenses.
- Outlook: The filing does not provide specific financial guidance or operational outlook, though the appointment signals a strategic focus on leveraging Dr. Schwartz's regulatory and clinical development expertise.
Investor Verification Checklist
- Verify the vesting schedule and expiration date of the 5,200 stock options granted to Dr. Schwartz.
- Confirm the total annual cash compensation of $45,000 for the new director role.
- Review the attached press release (Exhibit 99.1) for additional context on the Board's strategic direction.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.